Davita (NYSE:DVA)‘s stock had its “hold” rating reiterated by stock analysts at Royal Bank of Canada in a note issued to investors on Wednesday, The Fly reports. They currently have a $65.00 price objective on the stock. Royal Bank of Canada’s target price points to a potential upside of 18.16% from the company’s previous close.
A number of other research firms have also weighed in on DVA. UBS Group raised Davita from a “sell” rating to a “neutral” rating and decreased their target price for the stock from $64.00 to $59.00 in a report on Tuesday. Deutsche Bank began coverage on Davita in a report on Thursday, January 3rd. They set a “buy” rating and a $60.00 target price on the stock. ValuEngine lowered Davita from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Barclays began coverage on Davita in a report on Friday, December 14th. They set an “overweight” rating and a $70.00 target price on the stock. Finally, Raymond James lowered Davita from an “outperform” rating to a “market perform” rating and set a $63.44 target price on the stock. in a report on Sunday, December 2nd. Two analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $74.16.
Shares of Davita stock opened at $55.01 on Wednesday. Davita has a 52-week low of $48.25 and a 52-week high of $80.71. The company has a market capitalization of $8.95 billion, a P/E ratio of 16.57, a PEG ratio of 0.54 and a beta of 1.25. The company has a current ratio of 1.84, a quick ratio of 1.82 and a debt-to-equity ratio of 2.09.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in DVA. Pendal Group Ltd bought a new stake in Davita in the 3rd quarter valued at $961,000. Glenmede Trust Co. NA lifted its position in shares of Davita by 95.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 658,818 shares of the company’s stock valued at $47,189,000 after acquiring an additional 321,054 shares during the period. Morgan Stanley lifted its position in shares of Davita by 46.9% during the 2nd quarter. Morgan Stanley now owns 946,208 shares of the company’s stock valued at $65,704,000 after acquiring an additional 302,027 shares during the period. FMR LLC lifted its position in shares of Davita by 17.2% during the 3rd quarter. FMR LLC now owns 1,943,730 shares of the company’s stock valued at $139,229,000 after acquiring an additional 285,684 shares during the period. Finally, Capital Fund Management S.A. bought a new stake in shares of Davita during the 3rd quarter valued at $15,105,000. Institutional investors and hedge funds own 85.66% of the company’s stock.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: Swap
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.